Adlai Nortye Secures Supply Deals for Cancer Drug Trial

Under the new arrangements, Eli Lilly will provide cetuximab at no cost for clinical sites across the United States. Merck will simultaneously supply the same drug to support research facilities in Australia and China. Adlai Nortye remains the primary sponsor of the trial, which focuses on patients diagnosed with CEACAM5-enriched, RAS-addicted solid tumors.

These cancer types, including colorectal, pancreatic, and lung variants, frequently harbor RAS mutations where the CEACAM5 protein is overexpressed. Following the announcement, Adlai Nortye shares climbed 2.9% to $11.20 in premarket trading.